Yuekang Pharmaceutical: Subsidiary YKYY018 Inhalation Nebulizer for the Treatment and Prevention of Human Parainfluenza Virus Infection Indications Approved for Clinical Trials

Yuekang Pharmaceutical announced that its wholly-owned subsidiary, Beijing Yuekang Healthcare Technology Co., Ltd., recently received two "Clinical Trial Approval Notices" from the National Medical Products Administration approving the use of YKYY018 nebulized inhalation for the treatment and prevention of human metapneumovirus. YKYY018 nebulized inhalation is an internationally original fusion inhibitor drug developed independently by the company using its full-process AI platform. This product has already received clinical trial approvals for the prevention and treatment of respiratory syncytial virus infection from the U.S. Food and Drug Administration and the National Medical Products Administration in November and December 2025, respectively.